Looking for a specific product?

Make a search for products & suppliers, articles & news.

Bionor Pharma's "Kick, Kill & Boost" Strategy Advances

Bionor Pharma ASA (OSE: BIONOR) announces that the Company has chosen romidepsin for the planned combination study with Vacc-4x, after considering various HDAC inhibitors (HDACi). Romidepsin is marketed in the US as Istodax® by Celgene Corporation Inc. 

The "Kick, Kill" study is planned to be conducted by the HIV research team at
Aarhus University Hospital, led by Prof. Lars Østergaard. Prof.  Østergaard
presented the background and expectations of the study at Bionor Pharma's
Capital Markets Day in June. 


To read more, please visit the Bionor Pharma website.

Associated companies:

Related news